



Delay for cholecystectomy after common bile duct clearance with ERCP is just running after recurrent biliary event

Eric Bergeron¹ · Théo Doyon² · Thibaut Manière² · Étienne Désilets²

Received: 30 March 2023 / Accepted: 31 August 2023 / Published online: 19 September 2023
© The Author(s) 2023

Abstract

Background Gallstone disease will affect 15% of the adult population with concomitant common bile duct stone (CBDS) occurring in up to 30%. Endoscopic retrograde cholangiopancreatography (ERCP) is the mainstay of management for removal of CBDS, as cholecystectomy for the prevention of recurrent biliary event (RBE). RBE occurs in up to 47% if cholecystectomy is not done. The goal of this study was to evaluate the timing of occurrence of RBE after common bile duct clearance with ERCP and associated outcomes.

Methods The records of all patients who underwent ERCP for gallstone disease followed by cholecystectomy, in a single center from 2010 to 2022, were reviewed. All RBE were identified. Actuarial incidence of RBE was built. Patients with and without RBE were compared.

Results The study population is composed of 529 patients. Mean age was 58.0 (18–95). There were 221 RBE in 151 patients (28.5%), 39/151 (25.8%) having more than one episode. The most frequent RBE was acute cholecystitis (n = 104) followed by recurrent CBDS (n = 95). Median time for first RBE was 34 days. Actuarial incidence of RBE started from 2.5% at 7 days to reach 53.3% at 1 year. Incidence-rate of RBE was 2.9 per 100 person-months. Patients with RBE had significant longer hospitalisation time (11.7 vs 6.4 days; $P < 0.0001$), longer operative time (66 vs 48 min; $P < 0.0001$), longer postoperative stay (2.9 vs 0.9 days; $P < 0.0001$), higher open surgery rate (7.9% vs 1.3%; $P < 0.0001$), and more complicated pathology (23.8% vs 5.8%; $P < 0.0001$) and cholecystitis (64.2% vs 25.9%; $P < 0.0001$) as final diagnoses.

Conclusions RBE occurred in 28.5% of the subjects at a median time of 34 days, with an incidence of 2.5% as early as 1 week. Cholecystectomy should be done preferably within 7 days after common bile duct clearance in order to prevent RBE and adverse outcomes.

Keywords Endoscopic retrograde cholangiopancreatography · Choledocholithiasis · Gallstones · Recurrence · Cholecystectomy

Gallstone disease affects 7–15% of the adult population throughout the life [1, 2]. Prevalence may reach 80% at the age of 90 [3, 4]. Concomitant common bile duct stone (CBDS) occurs in 5–30% of the patients [2, 5–7].

Bile duct stone is the primary cause of acute pancreatitis [8, 9], which can be severe in 20–30% of the acute pancreatitis cases [9]. Overall mortality associated with pancreatitis

is 5% [9, 10] and can reach 20–30% in severe cases [10, 11]. Mortality associated with cholangitis may reach more than 10% [12].

Endoscopic retrograde cholangiopancreatography (ERCP) is the mainstay of management for the removal of CBDS [11, 13]. ERCP remains insufficient, since recurrence of CBDS occurs in up to 30% [4, 14], and recurrence of any related biliary events (RBE) in up to 47% of the cases [15, 16] despite clearance of the common bile duct (CBD). While ERCP fails to prevent further RBE [7, 16–18], cholecystectomy does prevent the RBE in majority of the cases [15, 17, 19, 20].

Cholecystectomy is associated with diminished recurrence of cholangitis [9, 21–23], pancreatitis [24–27], or any biliary events after clearance of CBD [7, 16, 18, 28–32].

✉ Eric Bergeron
eric.bergeron.med@ssss.gouv.qc.ca

¹ Department of Surgery, Charles-LeMoine Hospital, 3120, Boulevard Taschereau, Greenfield Park, QC J4V 2H1, Canada

² Department of Gastroenterology, Charles-LeMoine Hospital, Greenfield Park, QC, Canada

Guidelines thus recommend cholecystectomy early after common bile duct clearance but for varying time periods from 24 h to 4 weeks [2, 5–7, 12, 18, 20, 22, 32–41].

The goal of this study was to evaluate the timing of recurrent CBDS and other biliary events after clearance with ERCP. This study also aimed to identify the factors associated with this adverse outcome.

Materials and methods

This is a retrospective study of patients who underwent an endoscopic retrograde cholangiopancreatography (ERCP) for gallstone disease followed by cholecystectomy at Charles-LeMoyné Hospital, Quebec, Canada. Medical records were individually reviewed. Preoperative, operative and postoperative data were collected. This study has been approved by the Charles-LeMoyné Research Center and Charles-LeMoyné Hospital Ethics committee.

This study population is composed of patients aged 18 years or older who underwent ERCP followed by cholecystectomy from July 2010 to June 2022. Cholecystectomy records were extracted from the Operating Room database. ERCP records were extracted from the Endoscopy and Radiology databases. Database records were matched to identify patients who underwent ERCP before surgery. Exclusion criteria were: patients less than 18 years of age, ERCP for reasons other than gallstone disease, severe pancreatitis, cholecystectomy carried out before ERCP.

Information on the following independent variables was collected: age, sex, American Society of Anesthesiology (ASA) score, Charlson Comorbidity index, and initial diagnosis related to the biliary disease.

Each episode of care related with gallstone disease was reviewed. The following data were collected: types of admission (emergency or elective), diagnoses, index investigation or not and reasons to delay interventions, timing of all ERCPs, installation of stent, clearance of CBD or not, number of ERCPs needed for the clearance of CBD, number of ERCPs before surgery, types and recurrence of biliary events (RBE), date of surgery, reason if no index operation, and length of hospital stay for each admission.

The primary outcome variable was recurrence of all biliary events. Groups with or without RBE were compared. Secondary outcome variables were, duration of surgery, conversion or open surgery, surgical complications, postoperative stay, pathological status of the gallbladder and death.

Delay for clearance of CBD was calculated between the first presentation and the first ERCP that showed no residual CBDS. Delay for surgery after clearance was calculated from the ERCP with clearance of CBD and operation. The time of occurrence of RBE after clearance of the CBD was plotted on Kaplan–Meier curves and cholecystectomy was

the censored time. Chi-square test or two-tailed Student's *t* test were used for analyzing independent variables. For outcome variables, Chi-square test was used for discrete variables and ANOVA for continuous variables. Wilcoxon rank-sum test was used to compare medians. Statistical significance was established at $P < 0.05$.

Results

During the 12-year-study period (July 2010 to June 2022), 529 patients underwent cholecystectomy after having ERCP for gallstone related biliary disease. Among the studied patients, 57.1% were females (Table 1). Mean age of all the patients was 58.0 years, with 47.6% of them over 60 years, 29.2% over 70 years, and 8.7% over 80 years. Comorbidities were present in 52.2% of the patients, with 25.7% having more than one. Charlson Comorbidity index and distribution of ASA score are presented in Table 1.

Indication for ERCP was common bile duct stone without cholangitis or pancreatitis in 64.8% of the patients, cholangitis in 20.8%, and pancreatitis in 12.5%. A total of 624 ERCP were necessary to achieve initial clearance; one ERCP in 84.5%, two ERCP in 13.2%, three ERCP in 2.1%, and four ERCP in 0.2% of the cases. A stent was installed in 45.2% of the patients after initial presentation (Table 1). During the waiting period for cholecystectomy, 90 supplementary ERCP were carried out.

Cholecystectomy was carried out after a median time of 64 days (IQR 26–127 days) (Table 1). In 71 cases (13.4%), cholecystectomy was done during the same admission. In patients with delayed cholecystectomy, the median time before surgery was 80 days (IQR 41–143 days). There were 308 patients (58.2%) with clearance of CBD with ERCP at the initial admission. After exclusion of patients unfit for index surgery, 222 cases (42.0%) were referred for planned elective cholecystectomy, despite the clearance of the CBD at index admission.

While awaiting cholecystectomy, there were 221 episodes of RBE in 151 patients (28.5% of the studied patients); 39 patients with RBE (25.8% of those with RBE) had more than one episode. Cholecystitis was the most frequent gallstone related event in 47.0% (Table 2) with the first episode occurring at a median time of 29.5 days (IQR 15–82 days). At least one recurrent episode of common bile duct stone with or without pancreatitis/cholangitis occurred in 69 patients (13.0%), which occurred at a median of 42 days (IQR 25–94 days). In twelve of these patients (16.2%), there was more than one episode related to CBDS. Overall, the first RBE occurred at a median of 34 days (IQR 19–89 days). Figure 1 shows the actuarial occurrence of RBE, recurrent of CBDS and cholecystitis after clearance. Actuarial occurrence of RBE was 2.5% at 7 days up to 53.3% at 1 year. Figure 2

Table 1 Demographics and preoperative data

	Total	RBE	No-RBE	<i>P</i>
Total	529 (100.0)	151 (28.5)	378 (71.5)	
Female	302 (57.1)	93 (61.6)	210 (55.1)	0.1741
Male	227 (42.9)	58 (38.4)	171 (44.9)	
Age	58.0 ± 17.1	56.5 ± 16.4	57.6 ± 17.4	0.6148
18–59	277 (52.3)	89 (58.9)	188 (49.7)	
60+ (vs 18–59)	252 (47.6)	62 (41.0)	190 (50.3)	0.0556
70+ (vs 18–69)	155 (29.2)	37 (24.5)	118 (31.2)	0.1255
80+ (vs 18–79)	46 (8.7)	8 (5.3)	38 (10.0)	0.0886
Comorbidities				
Charlson comorbidity index	2.03 (1.78)	1.79 (1.71)	2.13 (1.80)	0.0527
ASA score	1.99 ± 0.62	1.93 ± 0.62	2.01 ± 0.62	0.1973
I	102 (19.3)	33 (21.8)	69 (18.2)	0.4462
II	333 (62.9)	96 (63.6)	237 (62.7)	
III	92 (17.4)	21 (13.9)	71 (18.8)	
IV	2 (0.4)	1 (0.7)	1 (0.3)	
V	0 (0.0)	0 (0.0)	0 (0.0)	
Initial diagnosis				
CBDS/no pancreatitis/no cholangitis	343 (64.8)	111 (73.5)	232 (61.4)	0.0104*
Cholangitis	110 (20.8)	29 (19.2)	81 (21.4)	
Pancreatitis	66 (12.5)	11 (7.3)	55 (14.5)	
Miscellaneous	10 (1.9)	0 (0.0)	10 (2.6)	
Initial reason to delay cholecystectomy				
External reference after index ERCP	222 (42.0)	85 (56.2)	137 (36.2)	0.1065
External reference for investigation	182 (34.4)	48 (31.8)	134 (35.4)	
Clearance of CBDS not completed	39 (7.4)	12 (7.9)	27 (7.1)	
Medical reason	8 (1.5)	4 (2.6)	4 (1.0)	
Miscellaneous	7 (1.3)	2 (1.3)	5 (1.3)	
Index cholecystectomy	71 (13.4)	0 (0.0)	71 (18.8)	
Stent during ERCP				
Clearance achieved	174 (32.9)	82 (54.3)	92 (24.3)	<0.0001*
Clearance not achieved	65 (12.2)	18 (11.9)	47 (12.4)	
No stent during ERCP	290 (54.8)	51 (33.8)	239 (63.2)	
Delay before clearance with ERCP (days)	13.8 ± 25.2	12.8 ± 23.0	15.1 ± 26.1	0.3457
Number of ERCP for clearance				
1	447 (84.5)	129 (85.4)	318 (84.1)	0.8012
2	70 (13.2)	20 (13.2)	50 (13.2)	
3	11 (2.1)	2 (1.3)	9 (2.4)	
4	1 (0.2)	0 (0.0)	1 (0.3)	
Delay between clearance and surgery				
Mean (days)	100.0 ± 170.9	139.3 ± 280.6	84.2 ± 93.2	0.0001*
Median (IQR 25–75) (days) all patients	64 (26–127)	83 (31–161)	58 (19–116)	<0.0001*
Median (IQR 25–75) (days) excl. index	80 (41–143)	83 (31–161)	78 (43–136)	0.0007*

Results are presented as n (%), mean ± standard error, median (interquartile range) when appropriate

*Statistically significant

shows the relative incidence of RBE in patients before cholecystectomy. The incidence-rate of RBE was 2.9 cases per 100 person-months.

Patients with and without RBE are also compared in Table 1. There was no difference in age and gender between

groups except for a tendency for more RBE in patients under 60 years of age. Globally, comorbidities and ASA are comparable between groups. RBE was significantly more frequent when initial diagnosis was CBDS with no associated pancreatitis or cholangitis (73.5% vs 61.4%; $P < 0.05$). RBE

Table 2 Types of recurrent biliary events (RBE)

Type	n (%)
Total ^a	221 (100.0)
Acute cholecystitis	104 (47.0)
Complicated ^b	33 (14.9)
Common bile duct stone	95 (43.0)
No pancreatitis/no cholangitis	65 (29.4)
Cholangitis	22 (9.9)
Pancreatitis	8 (3.6)
Biliary colic	16 (7.2)
ERCP complication	4 (1.8)
Liver abscess	2 (0.9)

^aIn 151 patients with RBE

^bPerforated, gangrenous or abscessed

was significantly more frequent when patients are referred for elective surgery after clearance is achieved with ERCP during the initial admission. RBE were also significantly more frequent when a stent was initially installed. In addition, within the group of patients with a stent, RBE occurred significantly more frequently if clearance was achieved (47.1% vs 27.7%; $P = 0.0067$). The number of ERCP necessary to complete clearance was not significantly different between groups.

The group of patients who suffered RBE had significantly longer hospital stay and postoperative stay (Table 3). They also experienced significantly longer operative time and significantly more open or conversion to open intervention. There was significantly more cholecystitis and complicated pathology in patients who had RBE. There was no difference in surgical complications and CBDS after surgery. Two injuries to the common bile duct occurred, one in each group. Globally, only 10 cases (1.9%) experience recurrence of


CBDS after cholecystectomy. Only one death was encountered in a patient with a severe septic shock.

Discussion

Almost half of the patients who undergo ERCP may suffer an episode of recurrent biliary event (RBE) even if clearance of the common bile duct (CBD) is achieved [16, 29]. RBE may be biliary colic, cholecystitis, hepatic abscess, and choledocholithiasis with or without pancreatitis or cholangitis [7, 22, 31]. Specifically, up to 30% of the patients may have recurrent common bile duct stone (CBDS) [14].

In this retrospective study, all types of gallstone related events after ERCP and clearance of CBD are included. The 28.5% occurrence of RBE after endoscopic CBDS extraction in this series correlates with a previously reported incidence of 17% to 60% [4, 12, 15, 19, 22, 25, 29, 31, 42, 43]. In two prospective randomized trials, after a wait-and-see policy, 24% [30] and 47% [29] of the patients presented with RBE, respectively. Schiphorst et al., found a 20% incidence of RBE at median of 22 days [31]. In a national registry study, Sandzen et al., found readmission for RBE within 1 year after acute biliary pancreatitis in, respectively, 62% and 76% of patients without cholecystectomy, depending upon if they had endoscopic sphincterotomy or not [33]. Regarding the cumulative incidence of RBE, it increases rapidly to reach 53.3% in 1 year (Fig. 1). At 1 week, the cumulative incidence was already 2.5% and increased almost linearly thereafter, with an incidence rate of 2.9% per 100 person-months. It means that patients are exposed to a steady risk of RBE while awaiting cholecystectomy. Huang et al. reported a 10.3% cumulative incidence of RBE at 60 days [7] while Cheng et al., reported 18.4% at 1 year [43]. However, these results were drawn from databases, with potential limitations

Fig. 1 Actuarial occurrence of acute cholecystitis, recurrent CBDS, and all types of RBE after clearance of the common bile duct with ERCP






Fig. 2 Incidence of recurrent biliary events over time

Table 3 Outcome variables

	Total	RBE	No-RBE	P
n (%)	529 (100.0)	151 (28.5)	378 (71.5)	
Initial length of stay (days)	4.89 ± 5.31	4.98 ± 5.55	4.85 ± 5.22	0.8062
Total length of stay (days)	7.89 ± 8.03	11.7 ± 11.2	6.37 ± 5.65	<0.0001*
Postoperative stay (days)	1.48 ± 3.14	2.92 ± 4.63	0.90 ± 2.03	<0.0001*
Failed planned 1-day surgery	83/366 (22.7)	37/78 (50.0)	46/288 (16.0)	<0.0001*
Duration of surgery (minutes)	53.9 ± 26.9	66.6 ± 34.0	48.8 ± 21.4	<0.0001*
Conversion/open surgery	17 (3.2)	12 (7.9)	5 (1.3)	<0.0001*
Surgical complications	26 (4.9)	11 (7.3)	15 (4.0)	0.1110
Final pathologic diagnosis: Cholecystitis	195 (36.9)	97 (64.2)	98 (25.9)	<0.0001
Complicated	58 (10.9)	36 (23.8)	22 (5.8)	<0.0001
CBDS recurrence after surgery	10 (1.9)	4 (2.6)	6 (1.6)	0.4057
Death	1 (0.3)	0 (0.0)	1 (0.3)	0.5270

Results are presented as n (%) and mean ± standard error when appropriate

*Statistically significant

of missing episodes, contrary to the present study in which all records were individually reviewed.

Just considering the recurrence of CBDS, its incidence is reported to occur between 9 and 30% [14, 30, 44–46]. In a nationwide population-based study, Park et al. found a first-time recurrence of CBDS in 11.3% of the patients [45]. In a prospective randomized study, Lau et al. found 18% of recurrent CBDS in patients who did not undergo cholecystectomy after 36 months of follow-up [30]. Kawaji et al. reported the occurrence of CBDS after ERCP in 12.4% of patients, and multiple recurrence in 21.5% of patients, who suffered a first recurrence of CBDS [44]. The present study shows, after exclusion of patients who underwent cholecystectomy during initial admission, that 15.5% of the patients had episodes

of recurrent CBDS. Also, considering only CBDS related episodes, 12 out of 74 patients (16.2%) had a second recurrence. Our results thus correlate with the reported iterative incidence of CDBS of 16% [47] and 23% [45], respectively. Multiple recurrences must thus be an important concern.

The high incidence of acute cholecystitis in this study is surprising (Table 2). We wonder if it is because we searched it more closely. In addition, patients with final pathology report of acute cholecystitis after elective cholecystectomy are even not included, since surgery is the censored time. Episodes of intercurrent acute cholecystitis are thus real RBE. Actually, acute cholecystitis after ERCP gained few attention [48] since most studies have mainly focused on the identification of CBDS recurrence [46]. We, however,

underline that cholecystitis is an important biliary event to be considered.

Cholecystectomy has been proven to prevent occurrence of RBE or readmissions after removal of choledocholithiasis [3, 7, 16, 20, 29–31]. Patients who underwent cholecystectomy after endoscopic extraction of CBDS showed a decreased hazard of RBE [21]. A Cochrane review by McAlister et al. demonstrated more RBE in wait-and-see strategy, with 35% of patients needed “rescue” cholecystectomy [16]. The gallbladder left in situ is an independent risk factor of RBE [44, 49, 50] and cholecystectomy provides a protective effect on the recurrence of CBDS [7, 30, 31, 43]. In fact, cholecystectomy has proven to be the strongest protective factor against readmissions [49, 51].

Cholecystectomy, either early or delayed, thus remains the best protector against RBE [29, 30, 51], approaching 90% of protection [7]. In addition, reviews showed that RBE is definitively lower if cholecystectomy is carried out early vs delayed (2–10% vs 24–47%) [13, 15, 29–31]. While a better reduction in the risk of RBE is achieved the sooner cholecystectomy is carried out [12, 42, 52], the definition of “early” cholecystectomy after endoscopic treatment of choledocholithiasis remains variable [1, 28, 53]. This is reflected in guidelines recommending early cholecystectomy after periods varying from 24 h to 4 weeks [2, 5–7, 12, 18, 20, 22, 32–41]. A recent study using a nationwide readmission database found that the lowest risk of readmission after ERCP for choledocholithiasis was index cholecystectomy [54]. A 5% risk of RBE has been demonstrated in PUNCHO trial within 24 h after pancreatitis [12].

There are several reasons for the decision to delay cholecystectomy including limited resources and operating room time, economic restraints, surgeon’s comfort and decision, and patient’s choice. [2, 31, 49, 54]. Another one is the belief and demonstration that cholecystectomy is more difficult after ERCP and endoscopic sphincterotomy [55–58]. However, cholecystectomy remains technically as difficult or even become more laborious if carried out later [15, 29, 30, 53, 55, 56, 58, 59], thus making sense to undertake early intervention [56, 59]. One limitation of this study is the difficulty to extract the reason to delay surgery after ERCP, i.e. surgeon’s choice vs patient’s preference. In the majority of cases of index ERCP, we figure out that it is the decision of the surgeon since the patients are admitted in the surgery service. During the follow-up, it remains also difficult to differentiate between the surgeon’s and the patient’s decision. However, the delay in planned elective surgery clearly and mainly relies on the lack of elective operating room availability.

Comorbidity is certainly another factor that is taken into consideration to delay cholecystectomy. Expectant management or delayed cholecystectomy is significantly more frequent in elderly and patients with more comorbidities [21,

23, 42, 60]. Aziz et al. showed that comorbidities are significantly associated with readmissions [60]. In the present study, elderly and patients with higher comorbidity score are not significantly associated with an increased incidence of RBE (Table 1). Yet, index cholecystectomy after ERCP have been demonstrated to be secure, with fewer or at least no increased risk of complications [12, 13, 25–27, 42, 49, 51], along with the prevention of RBE [3, 7, 16, 20, 21, 29–31, 43, 44, 49–51]. Age and comorbidity should not be an obstacle or a deterrent to proceed to early cholecystectomy or even at the index admission after the endoscopic removal of CBDS, except when risk is prohibitive [4].

The median delay that reaches 80 days before elective cholecystectomy is mainly imputable to the lack of resources and elective operating time. Analysis of the waiting period remains limited since information on the exact factors or reasons of delays are difficult to collate from the records retrospectively. In addition, considering emergency admission leading to “earlier” cholecystectomy in cases of RBE, the delay before elective would have been increased furthermore. Delays to elective surgery are definitively too long accounting for median times for occurrence of RBE or CBDS of respectively 34 and 42 days. Amazingly, half of the episodes thus occur before elective cholecystectomy. In a similar study, Schiphorst et al. found the same situation, with a median time between ERCP and elective cholecystectomy of 7 weeks while the median time was 22 days for the occurrence of RBE [31]. Limited resources are clearly identified as a significant problem [2, 31, 54] impeding implementation of guidelines [49].

The operative time in the group of patients who experienced RBE was significantly longer. Operative time may represent a surrogate of the difficulty of operation [53]. Operative time is higher after a previous ERCP [55], in emergency setting [28] and increases according to the number of episodes of cholecystitis [57]. Although the goal of this study was not to evaluate the relationship between cholecystitis and ERCP, its high incidence deserves to be considered as a contributing risk in the difficulty of delayed operation.

Unlike the majority of studies evaluating the occurrence and risk of RBE and complications in delayed cholecystectomy [7, 13, 17, 19, 21, 24, 28, 35], the present study rather examined the outcome in patients suffering RBE independently of the timing of surgery. Even if the occurrence of surgical complications did not reach statistical significance between groups, open cholecystectomy, either planned or converted, was significantly more frequent in patients who had RBE (Table 3). Schiphorst et al. also compared patients who had RBE and found an incidence of postoperative complications of 24% vs 11% in patients without RBE before cholecystectomy [31]. Open cholecystectomy is not necessarily associated with surgical

complications, and should not be considered as such, but certainly has a consequence on the length of hospital stay and recovery period. Higher rates of conversion have been associated with longer time between ERCP and cholecystectomy [55, 59, 61]. Tracy et al. also found a higher conversion rate despite the lack of any difference in surgical complications, emphasizing however, the impact on the postoperative length of stay [61].

Earlier cholecystectomy after ERCP and common bile duct extraction of stones has largely been evaluated. Risk of RBE is well demonstrated in delayed cholecystectomy [4, 12, 14, 15, 19, 22, 25, 29–31, 33, 42–47]. On the other hand, early cholecystectomy was not associated with increased surgical complications [4, 15, 27, 28, 31, 53] or conversion to open surgery [19, 25, 27, 28, 31, 53, 55, 62]. Some studies even demonstrated association with a better surgical outcome in early cholecystectomy [13, 29, 30, 59, 61]. Consequently, guidelines have been elaborated but with varying time frames [2, 5–7, 12, 18, 20, 22, 32–41] reflecting the lack of evidence of optimal timing of cholecystectomy [28, 34] from the prospective randomized controlled trials [18, 19].

UK guidelines [20], American Society Gastrointestinal Endoscopy (ASGE) [32] and European Society of Gastrointestinal Endoscopy (ESGE) [2] recommend cholecystectomy within 2 weeks after removal of common duct stone. We must, however, underline that the actuarial incidence of RBE is already 6.1% at 14 days with 15.5% of episodes occurring within 14 days. Other studies report 26.7% [19] and 31.3% [35] of RBE occurring within 2 weeks. Considering that index cholecystectomy has proven to be safe in patients fit for surgery [3, 7, 12, 13, 16, 20, 21, 25–27, 29–31, 42–44, 49–51], it should be the best option. In our study, no case of RBE occurred during index admission. Despite the guidelines to undergo index cholecystectomy [5, 6, 36–39], the compliance is recently reported to be less than 50% [39, 52, 54, 60], and even in decline, for unknown and complex reasons [42, 52, 54, 60].

For patients discharged without cholecystectomy or referred on external basis, with or without ERCP and clearance, the investigation must be rapidly actualized [12, 42, 52]. Some studies have shown a decrease in CBDS recurrence and cholangitis using a prophylactic stent [63, 64]. However, a significant increase in RBE in patients who had a stent, even if clearance was achieved, was found in this study (Table 1), but this includes an important proportion of cholecystitis. We emphasize that the goal of this study was not to specifically address the contribution of stenting. Moreover, conclusions about prophylactic stenting also remain limited since the reason to leave a stent is difficult to obtain from a retrospective point of view (choice of endoscopist, edema, bleeding, prophylactic). While stenting may be an effective step for definitive clearance of CBDS [65], cholecystectomy

soon after clearance remains necessary and should not wait for the removal of the stent [64].

A recent systematic review and meta-analysis concluded that surgery should be coordinated within preferably 72 h [62, 66]. The major impediment to proceed early is the lack of elective time, as reported by others [18, 49, 54]. Even if surgeons believe that surgery should be delayed, almost half of the elective cholecystectomy procedures are carried out after 3 months [31, 49]. So, performing cholecystectomy during the same admission, using an acute care surgery model, would considerably decrease the elective burden [22, 67]. There is no local expertise for laparoscopic common bile duct exploration (LCBDE). Developing this evolving modality could help to further alleviate the number of interventions, complications of ERCP, hospital stays, costs, and burden of elective interventions [68–71]. The problem of operating room availability for acute care surgery would, however, remain. A coordinated fast track investigation and treatment, with a dedicated team and institutional commitment towards fulfillment of guidelines remains mandatory [72]. Also, continuous and rigorous evaluation in the quality of care and compliance with guidelines should be implemented [34, 67, 73, 74].

The single-centre retrospective design of this study presents some strengths and limitations. Inasmuch as all charts were individually reviewed, missing data should be minimal, unlike the data taken from registries. In this way, all RBE have probably been identified, since readmissions and ERCP reports are readily available. Only patients who underwent cholecystectomy were included, making it not possible to draw conclusions on patients without surgery. Patients who had intraoperative cholangiogram are also not included since they did not have ERCP before cholecystectomy. Conclusions cannot be drawn for highly severe comorbid patients with $ASA \geq 4$. Moreover, very elderly patients (80+) remain underrepresented. In addition, the reason for the decision not to operate, nor the precise moment when the cholecystectomy was exactly planned, were difficult to extract from the hospital records. Hence, patients with a decision not to operate are not included and conclusions cannot be drawn for this specific group. Patients may be missed if they were seen in another center for either RBE, surgery, or postoperative complications. It was also not possible to identify patients who could have died or suffered major complications (related or not with gallstone disease) impeding surgery. Notwithstanding these limitations of this study and its retrospective design, the total number of patients and distribution between groups, renders the analysis and conclusions, in our opinion, highly valuable.

In conclusion, this study highlighted the following after clearance of CBDS with ERCP:

- RBE occurred in 28.5% of patients.

- RBE recurred in 25.8% of patients after a first episode of RBE.
- Actuarial occurrence of RBE start from 2.5% at 7 days to reach 53.3% in 1 year.
- Incidence rate of RBE remains steady at 2.9 per 100 person-months before cholecystectomy.
- Comorbidity and elderly are not significantly associated with the occurrence of RBE.
- RBE is associated with a significantly higher risk of difficult operation, conversion and surgical complications.

Our results reinforce that cholecystectomy should be carried out, should the patient be fit for surgery, the earliest after ERCP for gallstone disease and clearance of CBD. Ideally, cholecystectomy should be carried during the same admission, or within the very first few days, but definitively not beyond seven days. Otherwise, any delay just significantly runs after recurrent biliary event.

Funding There was no funding for this work and authors did not receive any grant.

Declarations

Disclosures Thibaut Maniere declares payment for mentorship for Olympus, and lectures for Boston Scientific and Pendopharma, but not for this work. Etienne Désilets declares payment for lectures for the “Association des Gastroentérologues du Québec” and the “Fédération des médecins spécialistes du Québec”, but not for this work. Eric Bergeron, Théo Doyon, Thibaut Maniere and Etienne Désilets have no conflicts of interest or financial ties to disclose.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

1. Wu Y, Xu CJ, Xu SF (2021) Advances in risk factors for recurrence of common bile duct stones. *Int J Med Sci* 18:1067–1074
2. Manes G, Paspatis G, Aabakken L, Anderloni A, Arvanitakis M, Ah-Soune P, Barthet M, Domagk D, Dumonceau JM, Gigot JF, Hritz I, Karamanolis G, Laghi A, Mariani A, Paraskeva K, Pohl J, Ponchon T, Swahn F, Ter Steege RWF, Tringali A, Vezakis A, Williams EJ, van Hooft JE (2019) Endoscopic management of common bile duct stones: European Society of Gastrointestinal Endoscopy (ESGE) guideline. *Endoscopy* 51:472–491
3. Khan MA, Khan Z, Tombazzi CR, Gadiparthi C, Lee W, Wilcox CM (2018) Role of cholecystectomy after endoscopic sphincterotomy in the management of choledocholithiasis in high-risk patients: a systematic review and meta-analysis. *J Clin Gastroenterol* 52:579–589
4. Edwards K, Johnson G, Bednarz J, Hardy K, McKay A, Vergis A (2021) Long-term outcomes of elderly patients managed without early cholecystectomy after endoscopic retrograde cholangiopancreatography and sphincterotomy for choledocholithiasis. *Cureus*. <https://doi.org/10.7759/cureus.19074>
5. ASGE Standards of Practice Committee, Buxbaum JL, Abbas Fehmi SM, Sultan S, Fishman DS, Qumseyra BJ, Cortes VK, Schilperoort H, Kysh L, Matsuoka L, Yachimski P, Agrawal D, Gurudu SR, Jamil LH, Jue TL, Khashab MA, Law JK, Lee JK, Naveed M, Sawhney MS, Thosani N, Yang J, Wani SB (2019) ASGE guideline on the role of endoscopy in the evaluation and management of choledocholithiasis. *Gastrointest Endosc* 89:1075–1105
6. Working Group IAP/APA Acute Pancreatitis Guidelines (2013) IAP/APA evidence-based guidelines for the management of acute pancreatitis. *Pancreatol* 13(4 Suppl 2):e1–e15
7. Huang RJ, Barakat MT, Girotra M, Banerjee S (2017) Practice patterns for cholecystectomy after endoscopic retrograde cholangiopancreatography for patients with choledocholithiasis. *Gastroenterology* 153:762–771
8. Yadav D, Lowenfels AB (2013) The epidemiology of pancreatitis and pancreatic cancer. *Gastroenterology* 144:1252–1261
9. Shah AP, Mourad MM, Bramhall SR (2018) Acute pancreatitis: current perspectives on diagnosis and management. *J Inflamm Res* 11:77–85
10. Phillip V, Steiner JM, Algül H (2014) Early phase of acute pancreatitis: assessment and management. *World J Gastrointest Pathophysiol* 5:158–168
11. Mulki R, Shah R, Qayed E (2019) Early vs late endoscopic retrograde cholangiopancreatography in patients with acute cholangitis: a nationwide analysis. *World J Gastrointest Endosc* 11:41–53
12. da Costa DW, Bouwense SA, Schepers NJ, Besselink MG, van Santvoort HC, van Brunshot S, Bakker OJ, Bollen TL, Dejong CH, van Goor H, Boermeester MA, Bruno MJ, van Eijck CH, Timmer R, Weusten BL, Consten EC, Brink MA, Spanier BW, Bilgen EJS, Nieuwenhuijs VB, Hofker HS, Rosman C, Voorburg AM, Bosscha K, van Duijvendijk P, Gerritsen JJ, Heisterkamp J, de Hingh IH, Witteman BJ, Kruij PM, Scheepers JJ, Molenaar IQ, Schaapherder AF, Manusama ER, van der Waaï LA, van Unen J, Dijkgraaf MG, van Ramshorst B, Gooszen HG, Boerma D, Dutch Pancreatitis Study Group (2015) Same-admission versus interval cholecystectomy for mild gallstone pancreatitis (PONCHO): a multicentre randomised controlled trial. *The Lancet* 386:1261–1268
13. Hoilat GJ, Hoilat JN, Abu-Zaid A, Raleigh J, Tot J, Mandal A, Sostre V, Carvounis C, Sapkota B (2021) Impact of early cholecystectomy on the readmission rate in patients with acute gallstone cholangitis: a retrospective single-centre study. *BMJ Open Gastroenterol*. <https://doi.org/10.1136/bmjgast-2021-000705>
14. Fritz E, Kirchgatterer A, Hubner D, Aschl G, Hinterreiter M, Stadler B, Knoflach P (2006) ERCP is safe and effective in patients 80 years of age and older compared with younger patients. *Gastrointest Endosc* 64:899–905
15. Reinders JS, Goud A, Timmer R, Kruij PM, Witteman BJ, Smakman N, Breumelhof R, Donkervoort SC, Jansen JM, Heisterkamp J, Grubben M, van Ramshorst B, Boerma D (2010) Early laparoscopic cholecystectomy improves outcomes after endoscopic sphincterotomy for choledochocystolithiasis. *Gastroenterology* 138:2315–2320

16. McAlister VC, Davenport E, Renouf E (2007) Cholecystectomy deferral in patients with endoscopic sphincterotomy. *Cochrane Database Syst Rev*. <https://doi.org/10.1002/14651858.CD006233>
17. Lee JM, Chung WC, Sung HJ, Kim YJ, Youn GJ, Jung YD, Choi S, Jeon EJ (2017) Factor analysis of recurrent biliary events in long-term follow up of gallstone pancreatitis. *J Dig Dis* 18:40–46
18. National Institute for Health and Care Excellence: Guidelines (2014) Gallstone disease: diagnosis and management of cholelithiasis, cholecystitis and choledocholithiasis. National Institute for Health and Care Excellence (NICE), London
19. Jee SL, Jarmin R, Lim KF, Raman K (2018) Outcomes of early versus delayed cholecystectomy in patients with mild to moderate acute biliary pancreatitis: a randomized prospective study. *Asian J Surg* 41:47–54
20. Williams E, Beekingham I, El Sayed G, Gurusamy K, Sturgess R, Webster G, Young T (2017) Updated guideline on the management of common bile duct stones (CBDs). *Gut* 66:765–782
21. Chen TS, Lin XH, Peng YL, Luo JC, Chen YT, Hou MC, Lee FY (2017) Cholecystectomy decreased the recurrent cholangitis after clearance of bile duct stones by ERCP in patients with gallstone-related cholangitis. *J Chin Med Assoc* 80:690–696
22. Li S, Su B, Chen P, Hao J (2018) Risk factors for recurrence of common bile duct stones after endoscopic biliary sphincterotomy. *J Int Med Res* 46:2595–2605
23. Mattila A, Mrena J, Kellokumpu I (2017) Expectant management of gallbladder stones after endoscopic removal of common bile duct stones. *Int J Surg* 43:107–111
24. Kamal A, Akhuemonkhan E, Akshintala VS, Singh VK, Kallou AN, Hutfless SM (2017) Effectiveness of guideline-recommended cholecystectomy to prevent recurrent pancreatitis. *Am J Gastroenterol* 112:503–510
25. van Baal MC, Besselink MG, Bakker OJ, van Santvoort HC, Schaapherder AF, Nieuwenhuijs VB, Gooszen HG, van Ramshorst B, Boerma D, Dutch Pancreatitis Study Group (2012) Timing of cholecystectomy after mild biliary pancreatitis: a systematic review. *Ann Surg* 255:860–866
26. Nguyen GC, Rosenberg M, Chong RY, Chong CA (2012) Early cholecystectomy and ERCP are associated with reduced readmissions for acute biliary pancreatitis: a nationwide, population-based study. *Gastrointest Endosc* 75:47–55
27. Noel R, Arnelo U, Lundell L, Hammarqvist F, Jumaa H, Enochsson L, Sandblom G (2018) Index versus delayed cholecystectomy in mild gallstone pancreatitis: results of a randomized controlled trial. *HPB* 20:932–938
28. Abdalkodous M, Franklyn J, Ibrahim R, Yao L, Zainudin N, Aroori S (2022) Delayed cholecystectomy following endoscopic retrograde cholangio-pancreatography is not associated with worse surgical outcomes. *Surg Endosc* 36:2987–2993
29. Boerma D, Rauws EA, Keulemans YC, Janssen IM, Bolwerk CJ, Timmer R, Boerma EJ, Obertop H, Huibregtse K, Gouma DJ (2002) Wait-and-see policy or laparoscopic cholecystectomy after endoscopic sphincterotomy for bile-duct stones: a randomised trial. *Lancet* 360:761–765
30. Lau JY, Leow CK, Fung TM, Suen BY, Yu LM, Lai PB, Lam YH, Ng EK, Lau WY, Chung SS, Sung JJ (2006) Cholecystectomy or gallbladder in situ after endoscopic sphincterotomy and bile duct stone removal in Chinese patients. *Gastroenterology* 130:96–103
31. Schiphorst AH, Besselink MG, Boerma D, Timmer R, Wiezer MJ, van Erpecum KJ, Broeders IA, van Ramshorst B (2008) Timing of cholecystectomy after endoscopic sphincterotomy for common bile duct stones. *Surg Endosc* 22:2046–2050
32. ASGE Standards of Practice Committee, Maple JT, Ikenberry SO, Anderson MA, Appalaneni V, Decker GA, Early D, Evans JA, Fanelli RD, Fisher D, Fisher L, Fukami N, Hwang JH, Jain R, Jue T, Khan K, Krinsky ML, Malpas P, Ben-Menachem T, Sharaf RN, Dominitz JA (2001) The role of endoscopy in the management of choledocholithiasis. *Gastrointest Endosc* 74:731–744
33. Sandzén B, Haapamäki MM, Nilsson E, Stenlund HC, Oman M (2009) Cholecystectomy and sphincterotomy in patients with mild acute biliary pancreatitis in Sweden 1988–2003: a nationwide register study. *BMC Gastroenterol*. <https://doi.org/10.1186/1471-230X-9-80>
34. Green R, Charman SC, Palser T (2017) Early definitive treatment rate as a quality indicator of care in acute gallstone pancreatitis. *Br J Surg* 104:1686–1694
35. Ito K, Ito H, Whang EE (2008) Timing of cholecystectomy for biliary pancreatitis: do the data support current guidelines? *J Gastrointest Surg* 12:2164–2170
36. Mayumi T, Okamoto K, Takada T, Strasberg SM, Solomkin JS, Schlossberg D, Pitt HA, Yoshida M, Gomi H, Miura F, Garden OJ, Kiriya S, Yokoe M, Endo I, Asbun HJ, Iwashita Y, Hibi T, Umezawa A, Suzuki K, Itoi T, Hata J, Han HS, Hwang TL, Dervenis C, Asai K, Mori Y, Huang WS, Belli G, Mukai S, Jagannath P, Cherqui D, Kozaka K, Baron TH, de Santibañes E, Higuchi R, Wada K, Gouma DJ, Deziel DJ, Liau KH, Wakabayashi G, Padbury R, Jonas E, Supe AN, Singh H, Gabata T, Chan ACW, Lau WY, Fan ST, Chen MF, Ker CG, Yoon YS, Choi IS, Kim MH, Yoon DS, Kitano S, Inomata M, Hirata K, Inui K, Sumiyama Y, Yamamoto M (2018) Tokyo guidelines 2018: management bundles for acute cholangitis and cholecystitis. *J Hepatobiliary Pancreat Sci* 25:96–100
37. Tenner S, Baillie J, DeWitt J, Vege SS, American College of Gastroenterology (2013) American College of Gastroenterology guideline: management of acute pancreatitis. *Am J Gastroenterol* 108:1400–1415
38. Crockett SD, Wani S, Gardner TB, Falck-Ytter Y, Barkun AN, American Gastroenterological Association Institute Clinical Guidelines Committee (2018) American Gastroenterological Association Institute guideline on initial management of acute pancreatitis. *Gastroenterology* 154:1096–1101
39. Greenberg JA, Hsu J, Bawazeer M, Marshall J, Friedrich JO, Nathens A, Coburn N, May GR, Pearsall E, McLeod RS (2016) Clinical practice guideline: management of acute pancreatitis. *Can J Surg* 59:128–140
40. Working Party of the British Society of Gastroenterology; Association of Surgeons of Great Britain and Ireland; Pancreatic Society of Great Britain and Ireland; Association of Upper GI Surgeons of Great Britain and Ireland (2005) UK guidelines for the management of acute pancreatitis. *Gut*. <https://doi.org/10.1136/gut.2004.057026>
41. Warttig S, Ward S, Rogers G, Guideline Development Group (2014) Diagnosis and management of gallstone disease: summary of NICE guidance. *BMJ*. <https://doi.org/10.1136/bmj.g6241>
42. Krishna SG, Kruger AJ, Patel N, Hinton A, Yadav D, Conwell DL (2018) Cholecystectomy during index admission for acute biliary pancreatitis lowers 30-day readmission rates. *Pancreas* 47:996–1002
43. Cheng CT, Yeh CN, Chiang KC, Yeh TS, Chen KF, Chen SW (2018) Effects of cholecystectomy on recurrent biliary complications after endoscopic treatment of common bile duct stone: a population-based cohort study. *Surg Endosc* 32:1793–1801
44. Kawaji Y, Isayama H, Nakai Y, Saito K, Sato T, Hakuta R, Saito T, Takahara N, Mizuno S, Kogure H, Matsubara S, Tada M, Kitano M, Koike K (2019) Multiple recurrences after endoscopic removal of common bile duct stones: a retrospective analysis of 976 cases. *J Gastroenterol Hepatol* 34:1460–1466
45. Park BK, Seo JH, Jeon HH, Choi JW, Won SY, Cho YS, Lee CK, Park H, Kim DW (2018) A nationwide population-based study of common bile duct stone recurrence after endoscopic stone removal in Korea. *J Gastroenterol* 53:670–678

46. Lee JK, Ryu JK, Park JK, Yoon WJ, Lee SH, Lee KH, Kim YT, Yoon YB (2006) Risk factors of acute cholecystitis after endoscopic common bile duct stone removal. *World J Gastroenterol* 12:956–960
47. Ando T, Tsuyuguchi T, Okugawa T, Saito M, Ishihara T, Yamaguchi T, Saisho H (2003) Risk factors for recurrent bile duct stones after endoscopic papillotomy. *Gut* 52:116–121
48. Cao J, Peng C, Ding X, Shen Y, Wu H, Zheng R, Wang L, Zou X (2018) Risk factors for post-ERCP cholecystitis: a single-center retrospective study. *BMC Gastroenterol*. <https://doi.org/10.1186/s12876-018-0854-3>
49. Garg SK, Bazerbachi F, Sarvepalli S, Majumder S, Vege SS (2019) Why are we performing fewer cholecystectomies for mild acute biliary pancreatitis? Trends and predictors of cholecystectomy from the National Readmissions Database (2010–2014). *Gastroenterol Rep* 7:331–337
50. Kim SB, Kim TN, Chung HH, Kim KH (2017) Small gallstone size and delayed cholecystectomy increase the risk of recurrent pancreatobiliary complications after resolved acute biliary pancreatitis. *Dig Dis Sci* 62:777–783
51. Qayed E, Shah R, Haddad YK (2018) Endoscopic retrograde cholangiopancreatography decreases all-cause and pancreatitis readmissions in patients with acute gallstone pancreatitis who do not undergo cholecystectomy: a nationwide 5-year analysis. *Pancreas* 47:425–435
52. Bilal M, Kline KT, Trieu JA, Saraireh H, Desai M, Parupudi S, Abougergi MS (2019) Trends in same-admission cholecystectomy and endoscopic retrograde cholangiopancreatography for acute gallstone pancreatitis: a nationwide analysis across a decade. *Pancreatol* 19:524–530
53. Goel A, Kothari S, Bansal R (2021) Comparative analysis of early versus late laparoscopic cholecystectomy following endoscopic retrograde cholangiopancreatography in cases of cholelithiasis with choledocholithiasis. *Euroasian J Hepatogastroenterol* 11:11–13
54. Berndtson AE, Costantini TW, Smith AM, Edwards SB, Kobayashi L, Doucet JJ, Godat LN (2022) Management of choledocholithiasis in the elderly: same-admission cholecystectomy remains the standard of care. *Surgery* 172:1057–1064
55. Reinders JS, Gouma DJ, Heisterkamp J, Tromp E, van Ramshorst B, Boerma D (2013) Laparoscopic cholecystectomy is more difficult after a previous endoscopic retrograde cholangiography. *HPB* 15:230–234
56. Ahn KS, Kim YH, Kang KJ, Kim TS, Cho KB, Kim ES (2015) Impact of preoperative ERCP on laparoscopic cholecystectomy: a case-controlled study with propensity score matching. *World J Surg* 39:2235–2242
57. Lucocq J, Scollay J, Patil P (2022) Elective laparoscopic cholecystectomy: recurrent biliary admissions predispose to difficult cholecystectomy. *Surg Endosc* 36:6403–6409
58. Prajapati RP, Vairagar SR, Banker AM, Khajanchi MU (2022) Optimal timing of laparoscopic cholecystectomy post-endoscopic retrograde cholangiography and common bile duct clearance: a prospective observational study. *J Minim Access Surg* 18:438–442
59. Salman B, Yilmaz U, Kerem M, Bedirli A, Sare M, Sakrak O, Tatlicioglu E (2009) The timing of laparoscopic cholecystectomy after endoscopic retrograde cholangiopancreatography in cholelithiasis coexisting with choledocholithiasis. *J Hepatobiliary Pancreat Surg* 16:832–836
60. Aziz H, Segalini N, Ahmed Z, Ahmad S, Goodman MD, Hertl M (2022) National trends in cholecystectomy and endoscopic retrograde cholangiopancreatography during index hospitalization for mild gallstone pancreatitis. *World J Surg* 46:524–530
61. Tracy BM, Paterson CW, Torres DM, Young K, Hochman BR, Zielinski MD, Burruss SK, Mulder MB, Yeh DD, Gelbard RB, EAST Retained Common Bile Duct Stones Study Group (2020) Risk factors for complications after cholecystectomy for common bile duct stones: an EAST multicenter study. *Surgery* 168:62–66
62. Friis C, Rothman JP, Burcharth J, Rosenberg J (2018) Optimal timing for laparoscopic cholecystectomy after endoscopic retrograde cholangiopancreatography: a systematic review. *Scand J Surg* 107:99–106
63. Choi JH, Lee TY, Cheon YK (2021) Effect of stent placement on stone recurrence and post-procedural cholangitis after endoscopic removal of common bile duct stones. *Korean J Intern Med* 36(Suppl 1):S27–S34
64. Kawabata H, Kawakatsu Y, Yamaguchi K, Sone D, Inoue N, Ueda Y, Okazaki Y, Hitomi M, Miyata M, Motoi S, Fukuda K, Shimizu Y (2019) Prophylactic biliary stenting before cholecystectomy in patients with gallstones and common bile duct stones. *Gastroenterol Res* 12:191–197
65. Attaallah W, Cingi A, Karpuz S, Karakus M, Gunal O (2016) Do not rush for surgery; stent placement may be an effective step for definitive treatment of initially unextractable common bile duct stones with ERCP. *Surg Endosc* 30:1473–1479
66. Wu K, Xiao L, Xiang J, Huan L, Xie W (2022) Is early laparoscopic cholecystectomy after clearance of common bile duct stones by endoscopic retrograde cholangiopancreatography superior? A systematic review and meta-analysis of randomized controlled trials. *Medicine*. <https://doi.org/10.1097/MD.00000000000031365>
67. Hardy K, Metcalfe J, Clouston K, Vergis A (2019) The impact of an acute care surgical service on the quality and efficiency of care outcome indicators for patients with general surgical emergencies. *Cureus*. <https://doi.org/10.7759/cureus.5036>
68. Zhu J, Wang G, Xie B, Jiang Z, Xiao W, Li Y (2023) Minimally invasive management of concomitant gallstones and common bile duct stones: an updated network meta-analysis of randomized controlled trials. *Surg Endosc* 37:1683–1693. <https://doi.org/10.1007/s00464-022-09723-8>
69. Lyu Y, Cheng Y, Li T, Cheng B, Jin X (2019) Laparoscopic common bile duct exploration plus cholecystectomy versus endoscopic retrograde cholangiopancreatography plus laparoscopic cholecystectomy for cholecystocholedocholithiasis: a meta-analysis. *Surg Endosc* 33:3275–3286
70. Prasson P, Bai X, Zhang Q, Liang T (2016) One-stage laparoendoscopic procedure versus two-stage procedure in the management for gallstone disease and biliary duct calculi: a systemic review and meta-analysis. *Surg Endosc* 30:3582–3590
71. Singh AN, Kilambi R (2018) Single-stage laparoscopic common bile duct exploration and cholecystectomy versus two-stage endoscopic stone extraction followed by laparoscopic cholecystectomy for patients with gallbladder stones with common bile duct stones: systematic review and meta-analysis of randomized trials with trial sequential analysis. *Surg Endosc* 32:3763–3776
72. Mador BD, Nathens AB, Xiong W, Panton ONM, Hameed SM (2017) Timing of cholecystectomy following endoscopic sphincterotomy: a population-based study. *Surg Endosc* 31:2977–2985
73. Enochsson L, Thulin A, Osterberg J, Sandblom G, Persson G (2013) The Swedish Registry of Gallstone Surgery and Endoscopic Retrograde Cholangiopancreatography (GallRiks): a nationwide registry for quality assurance of gallstone surgery. *JAMA Surg* 148:471–478
74. Vivian E, Cler L, Conwell D, Coté GA, Dickerman R, Freeman M, Gardner TB, Hawes RH, Kedia P, Krishnamoorthi R, Oduor H, Pandol SJ, Papachristou GI, Ross A, Sethi A, Varadarajulu S, Vege SS, Wassef W, Wilcox CM, Whitcomb DC, Wu BU, Yadav D, Ellison A, Habash S, Rastegari S, Reddy R, Yen T, Brooks MR, Tarnasky P (2019) Acute pancreatitis task force on quality: development of quality indicators for acute pancreatitis management. *Am J Gastroenterol* 114:1322–1342